title: Influence of short polyglutamine tracts and p160 coactivators on the transactivation of the androgen receptor.
abstract: The androgen receptor (AR) acting as a transcription factor plays a pivotal role in the occurrence and progression of prostate cancer (CaP). Several AR-related factors or modulators have been reported to influence AR activity. Whether and how these factors cooperatively modulate the AR activity has not been well defined. In the present study, the combined effect of p160 coactivators, short CAG length (encoding a short polyQ tract), and AR mutations on AR transactivation in a yeast system was evaluated. It was found that the short polyQ tract can upregulate the transactivation of the wild-type (WT) AR and partial-function (PF) AR mutants in response to a physiological level (10(-9) M) of dihydrotestosterone. Addition of a p160 coactivator (SRC-1 or TIF2) to the above systems resulted in a significant increase in the ligand-stimulated transactivation. Although the androgen antagonist bicalutamide could suppress the activity of androgen-activated WT or PF ARs, it was unable to do so for gain-of-function AR mutants. A combination of the short polyQ tract and coactivator TIF2 acted cooperatively on the WT AR and PF AR mutants to enhance their transactivation in response to either a low level of dihydrotestosterone (10(-10) M) or adrenal dehydroepiandrosterone. Taken together, this finding suggests that the modulated AR activity may involve early in the carcinogenesis of CaP. Additionally, these data support the concept that a given CaP in which the AR activity is modulated by multiple AR modulators may progress more readily to castrate resistance.
authors.affiliation: Department of Urology, University of California, Davis, School of Medicine, Sacramento, California 95817, USA.
authors.forename: Xu-Bao
authors.initials: XB
authors.lastname: Shi
authors.forename: Lingru
authors.initials: L
authors.lastname: Xue
authors.forename: Donghua
authors.initials: D
authors.lastname: Shi
authors.forename: Ralph W
authors.initials: RW
authors.lastname: deVere White
mesh_terms: D000726:Androgen Antagonists / Q000494:pharmacology; D000813:Anilides / Q000494:pharmacology; D013196:Dihydrotestosterone / Q000494:pharmacology; D006801:Humans; D008156:Luciferases / Q000378:metabolism; D008297:Male; D009154:Mutation; D009570:Nitriles / Q000494:pharmacology; D051958:Nuclear Receptor Coactivator 2 / Q000378:metabolism; D056918:Nuclear Receptor Coactivators / Q000235:genetics* / Q000378:metabolism; D010455:Peptides / Q000235:genetics / Q000494:pharmacology*; D011471:Prostatic Neoplasms / Q000235:genetics / Q000378:metabolism; D011944:Receptors, Androgen / Q000235:genetics* / Q000378:metabolism; D012441:Saccharomyces cerevisiae / Q000235:genetics / Q000378:metabolism; D014105:Tosyl Compounds / Q000494:pharmacology; D015533:Transcriptional Activation / Q000187:drug effects; D015854:Up-Regulation
chemical_list: D000726:Androgen Antagonists; D000813:Anilides; C498001:NCOA2 protein, human; D009570:Nitriles; D051958:Nuclear Receptor Coactivator 2; D056918:Nuclear Receptor Coactivators; D010455:Peptides; D011944:Receptors, Androgen; D014105:Tosyl Compounds; D013196:Dihydrotestosterone; C097188:polyglutamine; C053541:bicalutamide; D008156:Luciferases